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Abstract The ﬁrst evidence that plants represent a
valid, safe and cost-effective alternative to traditional
expression systems for large-scale production of
antigens and antibodies was described more than
10 years ago. Since then, considerable improvements
have been made to increase the yield of plant-
produced proteins. These include the use of signal
sequences to target proteins to different cellular
compartments, plastid transformation to achieve high
transgene dosage, codon usage optimization to boost
gene expression, and protein fusions to improve
recombinant protein stability and accumulation.
Thus, several HIV/SIV antigens and neutralizing
anti-HIV antibodies have recently been successfully
expressed in plants by stable nuclear or plastid
transformation, and by transient expression systems
based on plant virus vectors or Agrobacterium-
mediated infection. The current article gives an
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antibodies and provides an account of the use of
different strategies aimed at increasing the expression
of the accessory multifunctional HIV-1 Nef protein in
transgenic plants.
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Introduction
As stated by the latest UNAIDS AIDS epidemic
update (UNAIDS 2008 AIDS Epidemic update, http://
www.unaids.org), a total of 33.2 million people were
living with HIV in 2007. Twenty-ﬁve years since the
discovery of HIV, an effective vaccine is not yet
available. Current efforts in vaccine design have been
focused on subunit vaccines. The viral envelope
(Env) was initially considered the best candidate as
an inducer of neutralizing antibodies, but viral vari-
ability represents a barrier to obtain a broad immune
response (Walker and Burton 2008; Fauci et al.
2008). This problem could be overcome by a poly-
valent HIV vaccine, identifying constant domains on
the viral envelope necessary for virus–cell interaction
(Zolla-Pazner 2004) and through structural studies of
HIV envelope spikes created by gp41 and gp120
proteins (Walker and Burton 2008).
A vaccine able to induce sterilizing immunity still
remains a major challenge and modern vaccinology is
directed to inducing broad humoral and cellular
immune responses. Therefore, novel vaccines are
becoming increasingly complex, with several being
constituted by a combination of different recombi-
nant antigens. Both structural (Env, Gag) and non-
structural HIV-1 gene products (Rev, Tat, Nef) are
regarded as promising targets for multi-antigen
vaccine development, able to induce durable antivi-
ral immunity (Titti et al. 2007). Along with the
development of subunit vaccines, antibodies with
broad neutralizing activity against HIV-1 have
been proposed for both prophylactic and therapeutic
use (Trkola et al. 2005, 2008), although a major
limitation to this treatment is represented by the
necessity of a large-scale production system at low
cost.
To achieve this aim the use of plants of agronomic
relevance as bioreactors for large-scale production of
biopharmaceuticals and vaccine components repre-
sents a safe and economical alternative to traditional
production systems (Ma et al. 2003, 2005; Schillberg
et al. 2005). A number of studies have already shown
that structural and regulatory proteins of HIV or
related viruses could be successfully expressed in
plants by stable transformation or transient expression
strategies (Table 1). Moreover, very recently different
studies have been published on the over expression
and characterization of plant-derived anti-HIV neu-
tralizing antibodies (Table 2). In particular two mAbs,
the anti-gp120 2G12 (Trkola et al. 1996) and the anti-
gp41 2F5 (Conley et al. 1994), endowed with a broad
HIV neutralising activity, have been extensively
characterised. In the case of the 2G12 antibody,
directing the expression to the seed endosperm of
transgenic maize gave very promising results with
production levels of 40–100 mg/kg dry seed weight
(Ramessar et al. 2008; Rademacher et al. 2008).
Moreover, both studies showed that the neutralising
activity of the plant puriﬁed antibody was equivalent
to or even better than that of the CHO (Chinese
hamster ovary cells) derived 2G12. The same
antibody was also transiently expressed in N. benth-
amiana by leaf agroinﬁltration giving yields of
50 mg/kg of fresh biomass (Strasser et al. 2008). In
the case of the mAb 2F5 expressed in transgenic
tobacco plants it was shown that fusion of the heavy
and light chains to an elastin-like peptide (ELP) repeat
raised production yields mainly by enhancing protein
stability, furthermore this strategy could simplify
protein recovery and puriﬁcation (Floss et al. 2008).
The same antibody has been also expressed in
transgenic tobacco cell suspension cultures yielding
6.4 mg/kg wet cell weight (Sack et al. 2007). In this
case, although the plant derived 2F5 showed similar
antigen binding activity compared to its CHO derived
counterpart, HIV-1 neutralisation assays revealed a
decreased efﬁciency. Taken together these results
demonstrate the feasibility of expressing functional
HIV-1 neutralising antibodies in plants at yields
which could meet the requirements for a large-scale
economical production.
The ﬁrst examples reported in the literature of
expression in plants of HIV components relate to
sequences encoding epitopes of the viral Env (see
Table 1 for references). In both env products, gp120
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recognized by neutralizing antibodies have been
identiﬁed (Zolla-Pazner 2004). Some of these pro-
tective epitopes (2F5, V3 loop, etc.) have been
expressed, mainly fused to different plant virus
capsid proteins, able to self-assemble and generate
chimeric virus particles or chimeric virus like parti-
cles (VLP) (Table 1). Plant viruses and VLP were
easily puriﬁed and their immunogenicity has been
evaluated in animal models. Data have been reported
about the capability of recombinant plant viruses to
induce the production of antibodies able to neutralize
Table 1 Plant expressed
HIV-1 and SIV antigens
TMV tobacco mosaic virus,
TBSV tomato bushy stunt
virus, PVX potato virus X,
CPMV cowpea mosaic virus
Protein/peptide Plant Plant expression
system
Reference
Tat Spinach TMV plant viral vector Karasev et al. (2005)
Potato tuber Nuclear transformation Kim et al. (2004a)
Tomato Nuclear transformation Ramı ´rez et al. (2007)
Tobacco Nuclear transformation Webster et al. (2005)
Nef Tobacco Nuclear transformation Marusic et al. (2007),
Barbante et al. (2008),
de Virgilio et al. (2008)
Tobacco Plastid transformation Zhou et al. (2008),
McCabe et al. (2008)
Tomato Plastid transformation Zhou et al. (2008)
p24 Tobacco Nuclear transformation Obregon et al. (2006)
N. benthamiana TBSV plant viral vector Zhang et al. (2000)
Tobacco Nuclear transformation Zhang et al. (2002)
N. benthamiana TMV plant viral vector Meyers et al. (2008)
N. benthamiana Agroinﬁltration Meyers et al. (2008)
Tobacco Nuclear transformation Meyers et al. (2008)
Tobacco Plastid transformation Meyers et al. (2008)
Tobacco Plastid transformation Zhou et al. (2008),
McCabe et al. (2008)
Tomato Plastid transformation Zhou et al. (2008)
p17/p24 N. benthamiana Agroinﬁltration Meyers et al. (2008)
Tobacco Nuclear transformation Meyers et al. (2008)
Pr55Gag N. benthamiana TMV plant viral vector Meyers et al. (2008)
N. benthamiana Agroinﬁltration Meyers et al. (2008)
Tobacco Nuclear transformation Meyers et al. (2008)
SIVmac p27 Potato Nuclear transformation Kim et al. (2004b, c)
Env/gp120 V3 loop N. benthamiana TMV plant viral vector Yusibov et al. (1997)
Tobacco TMV plant viral vector Sugiyama et al. (1995),
Beachy et al. (1996)
Potato Nuclear transformation Kim et al. (2004d)
N. benthamiana TBSV plant viral vector Joelson et al. 1997)
Env/gp 130 SIVmac Corn kernel Nuclear transformation Horn et al. (2003)
Env/gp41 ELDKWA
epitope (662-667)
N. benthamiana PVX plant viral vector Marusic et al. (2001)
P1 peptide (649–684) N. benthamiana Agroinﬁltration Matoba et al. (2004)
Peptide (731–752) Cowpea CPMV plant viral
vector
Porta et al. (1994), McLain
et al. (1995, 1996),
Durrani et al. (1998),
McInerney et al. (1999)
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2001). Other studies demonstrated that Gag p17 and
p24/p17 capsid proteins can be produced in plants
using different expression strategies. A p24-immu-
noglobulin fusion molecule has been successfully
expressed by nuclear transformation in tobacco plants
and is able to elicit a T-cell and antibody immune
response in mice (Obregon et al. 2006). Different
results have been obtained with transiently expressed
p17/p24 which proved non immunogenic in mice but
was able to boost a humoral and T-cell response in
mice primed with gag DNA vaccine (Meyers et al.
2008). Similarly, the HIV regulatory protein Tat
produced in spinach did not induce a detectable
antibody response in mice orally immunized with
spinach leaves, but apparently mice were primed for
the subsequent tat DNA immunization (Karasev et al.
2005). Nevertheless, Tat antigen expressed in tomato
fruits was able to induce mucosal IgAs and serum
IgGs with neutralizing activity after oral immuniza-
tion in mice (Ramı ´rez et al. 2007).
Nef protein as a plant-made HIV vaccine
component
Among non-structural HIV-1 elements, the accessory
protein Nef is considered a good candidate for the
formulation of vaccines that combine both structural
and functional viral components. Nef is expressed
early during the viral life cycle and is necessary for
both high viral load and disease progression. More-
over, nef genes are highly conserved in all primate
lentiviruses (HIV-1, HIV-2, SIV). Experiments in a
transgenic mouse model showed that Nef proteins of
SIV and HIV are functionally interchangeable (Sin-
clair et al. 1997). In addition, data showed that
patients classiﬁed as long-term non-progressors have
alterations in the nef gene (Tobiume et al. 2002).
Recently, promising studies on the generation of
multi-component HIV vaccines, containing Nef, have
been published, reporting the ﬁrst clinical evaluation
of a multi-component vaccine containing recombi-
nant gp120 and Nef-Tat fusion proteins (Goepfert
et al. 2007) and the effects of a multi-component
genetic vaccine combining structural (Gag/Pol, Env)
and regulatory (Rev, Tat, Nef) antigens in the SIV-
Macaca animal model (Voss et al. 2003; Maggiorella
et al. 2007).
It has been demonstrated that nef gene yields two
main products: a full-length form of 27 kDa (p27)
and a truncated form of 25 kDa (p25), translated from
a second start codon and lacking the ﬁrst 18 amino
acids. The p27 protein is post-translationally modi-
ﬁed by the addition of a myristoyl group to the
N-terminus by which full-length Nef anchors to the
cytosolic side of cellular membranes. The p25 was
found in the cytosol, while the wild-type myristoy-
lated p27 was mainly membrane associated (Yu and
Felsted 1992). Nef contains several disordered
regions, which cause difﬁculties in the resolution of
its three-dimensional structure. However, the globu-
lar core domain and the N-terminal anchor domain
have been characterised by X-ray crystallography,
nuclear magnetic resonance (NMR) and NMR spec-
troscopy (Geyer et al. 1999; Geyer and Peterlin
Table 2 Plant expressed anti-HIV1 neutralizing antibodies
Antibody Species Promoter Compartment Plant expression
system
Yield Reference
2G12 Maize Endosperm
speciﬁc
Secretory Nuclear
transformation
75 mg/kg seed
dry weight
Ramessar et al.
(2008)
Maize Endosperm
speciﬁc
ER retention Nuclear
transformation
40 mg/kg seed
dry weight
Rademacher et al.
(2008)
N. benthamiana CaMV 35S Secretory Leaf
Agroinﬁltration
50 mg/kg fresh
leaf weight
Strasser et al.
(2008)
2F5 N. tabacum CaMV 35S ER retention Nuclear
transformation
ND Floss et al.
(2008)
N. tabacum cell
suspensions
CaMV 35S ER retention Nuclear
transformation
6.4 mg/kg wet
cell weight
Sack et al. (2007)
CaMV cauliﬂower mosaic virus, ND not determined
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1232001). The combination of data obtained from both
functional and structural studies allowed the identi-
ﬁcation of sequence motifs involved in protein
modiﬁcation, signalling and trafﬁcking (Geyer et al.
2001b). In general Nef affects protein trafﬁcking in
the host cells, down modulates cell-surface molecules
such as CD4 and MHC-I, while enhancing virus
infectivity and accelerating disease progression in
both humans and primate animal models (Roeth and
Collina 2006).
Both p27 and p25 isoforms have been expressed in
different biologicalsystemssuchasE.coli(Azad etal.
1994), yeast (Macreadie et al. 1998; Sire ´n et al. 2006),
insect cells (Kohleisen et al. 1996), mammalian cells
(Cooke et al. 1997) and plant cells (Marusic et al.
2007; Barbante et al. 2008; de Virgilio et al. 2008;
Zhou et al. 2008; McCabe et al. 2008).
In the following paragraphs we will focus on the
different biotechnological approaches developed by
several different laboratories aimed at obtaining high
accumulation of Nef in stable transgenics.
Targeting HIV-1 Nef to different plant cell
compartments
Yield and stability of plant recombinant proteins
are the main issues that must be addressed to
develop competitive commercial products. Several
approaches have been followed to express heterolo-
gous proteins at high levels and prevent protein
degradation in plants (Benchabane et al. 2008). Sub-
cellular targeting of recombinant proteins is one of
the major research topics in the ﬁeld of plant made
pharmaceuticals. A number of strategies are now in
place to direct proteins of interest to a speciﬁc
cellular compartment (e.g., apoplast, plastid, mito-
chondrion, vacuole, endoplasmic reticulum) by the
addition of speciﬁc targeting sequences (Streatﬁeld
2007).
To achieve stable and high-level expression of Nef
in transgenic plants a number of constructs were
designed either for nuclear or plastid transformation,
utilizing different signal or fusion peptides to direct
the expression of the viral protein to either the cytosol
or the secretory pathway. A schematic representation
indicating the most successful Nef expression strat-
egies and the relative yields are shown in Fig. 1 and
will be reviewed in the following sections.
Nef is stable in the cytosol of plant cells
In the ﬁrst study concerning plant recombinant Nef,
a panel of constructs were designed to direct the
expression of full-length N-terminal myristoylated
(p27), non-myristoylated (p27 mut) and truncated
form (p25) of Nef, to either the cytosol or the
secretory pathway (Marusic et al. 2007). In this work,
all constructs were tested initially by tobacco pro-
toplasts transfection followed by pulse chase analysis
to rapidly establish the most promising strategy for
protein expression in stable transgenic plants. All
cytosolic forms of Nef (p25, p27 and p27 mut)
appeared stable while small amounts of myristoylated
protein (p27) were associated to the plant cell
membrane. Constructs encoding p25 and p27 mut
were used to generate transgenic tobacco plants.
Quantitative ELISA revealed variable expression
levels in independently transformed plants ranging
between 0.18 and 0.7% of total soluble protein (TSP)
with an observed average value of 0.5% as reported
in Fig. 1. A small-scale puriﬁcation was successfully
attempted by IMAC chromatography taking advan-
tage of the (His)6 tag fused to the C-terminus of p27
mut (Marusic et al. 2007). The use of recombinant
Nef lacking myristoylation as part of a multi-
component vaccine is considered advantageous at
present (Peng et al. 2006). Indeed, deletion or
mutagenesis of the N-terminal myristoylation site
has been shown to abrogate the capacity of Nef to
down-regulate both MHC class I and CD4 cell-
surface molecules (Peng and Robert-Guroff 2001),
which normally prevent CTL-mediated lysis of
HIV-1-primary infected cells (Collins et al. 1998).
Attaching Nef to the cytosolic face of membranes
as a strategy to improve accumulation
A new, alternative strategy to improve p27 Nef
accumulation in transgenic plants, recently developed
by Barbante and colleagues (Barbante et al. 2008),
involves anchoring the molecule to the cytosolic face
of the endoplasmic reticulum (ER) membrane using
the C-terminal portion of the mammalian ER isoform
of cytochrome b5 (ER b5). ER b5 belongs to the tail-
anchored (TA) protein family, which are bound to
membranes by a C-terminally located hydrophobic
sequence (Borgese et al. 2003). TA proteins do not
Transgenic Res (2009) 18:499–512 503
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destination post-translationally; their functional
domains are exposed in the cytosol and only a short
C-terminal segment is translocated (Borgese et al.
1993). Consistently, the resulting topology of the
fusion molecule between Nef and the tail anchor of
ER b5 (Nef-TA) maintains the entire Nef portion in
its ideal cytosolic environment.
The Nef polypeptide anchored to the cytosolic face
of the ER membrane accumulated to higher levels
(morethanthreefold)comparedtoitssolublecytosolic
counterpartinalltransgenic plants analyzed (Barbante
etal.2008).Thevalueswere0.7%ofTSPsforNef-TA
with very little variability within each group. Analysis
of mRNA levels and pulse-chase experiments with
radioactive amino acids indicated that the higher
accumulation of Nef-TA is due to increased protein
stability. These results conﬁrm that the ER membrane
is a convenient target location for chimeric membrane
proteins because of its intrinsic plasticity and remod-
elling ability (Borgese et al. 2006), which is attuned to
the amount of protein that enters the secretory
pathway. In addition, being anchored to the ER
membrane, the Nef protein is likely to be less
susceptible to cytosolic degradation processes medi-
ated by the ubiquitin/proteasome pathway.
The successful production of recombinant vaccines
in transgenic plants also depends on the ease and
efﬁciency of puriﬁcation. Nef can be removed in vitro
from its TA taking advantage of an engineered
thrombin cleavage site (Barbante et al. 2008). This
opens the way to a puriﬁcation procedure involving
microsome preparation and then solubilization of the
molecule in a pure or nearly pure form by thrombin
cleavage.Thisnewstrategycouldbegenerallyusedfor
production purposes, when it is necessary to maintain
the heterologous protein in the reducing environment
of the cytosol and at the same time limit molecular
interactions with the host cell machinery.
Nef destiny in the secretory pathway: how to avoid
quality control degradation
The secretory pathway has been exploited extensively
for the production of recombinant pharmaceuticals in
N
ER
CHL
PB
CY
Fig. 1 Schematic representation of expression strategies used
to accumulate HIV-1 Nef in plant cells. Nef fusion to the
chimeric protein zeolin allows protein body formation (PB)
within the endoplasmic reticulum (ER) lumen (de Virgilio et al.
2008); fusion to the C-terminal portion of the mammalian ER
isoform of cytochrome b5( tail-anchor) anchors recombinant
protein to the cytosolic ER bilayer (Barbante et al. 2008);
fusion to HIV-1 p24 and chloroplast (CHL) transformation
(Zhou et al. 2008; McCabe et al. 2008); Nef cytosolic
expression (CY) (Marusic et al. 2007). Nucleus (N). Protein
expression levels are indicated and expressed as percentage of
total soluble protein
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important pharmaceutical proteins are secretory pro-
teins. The best known example is constituted by
immunoglobulins, which fortunately are rather resis-
tant to apoplastic proteases and therefore accumulate
to high amounts (Hiatt et al. 1989; Ma et al. 1995).
Further advantages reside in the ﬁnding that in all
eukaryotic cells the ER, which is the port of entry to
the secretory pathway, has low hydrolytic activity
and that soluble proteins can easily be retained in this
compartment by adding a signal peptide at the
N-terminus and the ER localization signals HDEL
or KDEL at the C-terminus (Vitale and Denecke
1999). Moreover, the ER of plant cells can tolerate
high accumulation of protein without compromising
cell functions (Wandelt et al. 1992). For proteins that
naturally reside in compartments other than the ER
but have a short half-life, targeting to the ER has
often increased accumulation (Doran 2006), although
there are exceptions (Patel et al. 2007; Yang et al.
2007).
Transient expression of Nef in the secretory
pathway of tobacco protoplasts, by the addition of
the signal peptide (sp) of the PR1 protein (Denecke
et al. 1990) to the N-terminal of both p25 and p27
Nef variants, resulted in marked instability during 5 h
chase suggesting misfolding and degradation by ER
quality control (Marusic et al. 2007). The ER is a
folding environment different from the cytosol,
mainly because it leads to the formation of disulﬁde
bonds and N-glycosylated proteins. These events
have evolved to favour solubility, stability and in
some cases biological activity of many secretory
proteins, but when they occur on proteins that
naturally reside in the cytosol and therefore are not
disulﬁde-bonded, they obviously can change protein
folding and have adverse effects. Experiments in
which synthesis has been performed in the presence
of the N-glycosylation inhibitor tunicamycin proved
that indeed Nef is glycosylated when inserted into the
ER, but also showed that the inhibitor does not
improve Nef stability in the secretory pathway
(Marusic et al. 2007). It therefore seems likely that
disulﬁde bonds are responsible for Nef misfolding.
It has been shown that in the cytosol Nef folding is
a slow process: at the end of 1 h pulse-labelling, Nef
Cys residues were still available for unproductive
in vitro disulﬁde bond formation, a feature that
was abolished by folding only upon 2 h chase. It
is conceivable that such a relatively long-term
availability of Cys residues for interactions leads
to in vivo formation of disulﬁde bonds in the
ER oxidizing environment, leading to misfolding
(Barbante et al. 2008). Addition of KDEL was unable
to rescue a structurally defective protein from deg-
radation by ER quality control (Frigerio et al. 2001).
This was also true in the case of Nef, where addition
of KDEL was incapable of rescuing the protein from
rapid degradation in transient expression (Barbante
et al. 2008). This further indicates that targeting Nef
to the lumen of the ER is likely to trigger its rapid
degradation, possibly by quality control.
As an alternative strategy, de Virgilio et al. (2008)
tried to promote the formation of protein bodies (PB)
containing Nef. PB are plant-speciﬁc, ER located,
insoluble polymers naturally formed by a number of
cereal seed storage proteins and are held together by
inter-chain disulﬁde bonds (Shewry et al. 1995). A
signiﬁcant amount of information is available regard-
ing the maize prolamin c-zein, which forms PB and
accumulates to high amounts also when expressed in
vegetative tissues (Coleman et al. 1996; Geli et al.
1994). It has been previously showed that a fragment
of c-zein, corresponding roughly to the N-terminal
half, is able to promote PB formation when fused to
the vacuolar storage protein phaseolin in the chimeric
protein zeolin (Mainieri et al. 2004). This leads to
accumulation of zeolin up to 3.5% of tobacco leaf
protein, roughly a tenfold improvement with respect
to accumulation of phaseolin-KDEL (Mainieri et al.
2004). The ﬁrst attempts to incorporate Nef into PB
were however, disappointing: fusion of Nef to the
same zein fragment used to construct zeolin, either in
N-terminal or C-terminal position, resulted in very
poor accumulation in transgenic tobacco leaves
(M. de Virgilio et al., unpublished data). Pulse-chase
in the presence of the vesicular trafﬁc inhibitor
brefeldin A and analysis of the processing of glycans
indicated that the chimeric proteins are degraded by
ER quality control. Conversely, fusion of the entire
zeolin sequence to Nef (zeolin-Nef) lead to PB
formation and markedly improved accumulation, to
about 1.5% of leaf protein, consistently in twenty
independent transgenic plants that were analyzed (de
Virgilio et al. 2008). Pulse-chase experiments and
comparison of transcript levels indicated that the
increased accumulation was exclusively due to a
marked improvement in protein stability. Electron
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zeolin-Nef forms PB in the ER, even if these are
smaller than those formed by zeolin.
The high instability of the fusions between Nef
and the zein domain, and of Nef-KDEL, indicate that
when a protein is recognized as structurally defective
by the ER machinery, it is difﬁcult to rescue it from
quality control degradation. It is not known if the
Nef-zein fusions are sorted for degradation before
they have the possibility to form disulﬁde-linked
polymers or after repeated unsuccessful attempts to
polymerize, but these ﬁndings place the ‘‘approval’’
by the ER quality control machinery as a prerequisite
for next steps in the synthesis of secretory proteins
that lead either to polymerization and formation of
PB or trafﬁc along the secretory pathway to other
destinations (de Virgilio et al. 2008; Vitale and
Boston 2008). On the other hand, the successful
accumulation of zeolin-Nef indicates that, when PB
formation occurs, this rescues an heterologous unsta-
ble protein from degradation by quality control,
markedly improving accumulation. Incorporation
into insoluble PB can also provide an advantage in
protein puriﬁcation, but ultimately it will probably be
necessary to remove the antigen from the appended
sequence. In zeolin-Nef, a thrombin cleavage site was
engineered between zeolin and the Nef sequence
(de Virgilio et al. 2008); when the chimeric protein
was solubilized with reducing agents, immunopre-
cipitated and treated in vitro with thrombin, Nef is
released in a soluble form (M. de Virgilio and A.
Vitale, unpublished data), indicating that, once
released from zeolin, Nef is not grossly misfolded.
However, further experiments are necessary to
determine if the recombinant antigen can also be
efﬁciently released from insoluble PB, thus making
puriﬁcation cost-effective.
Chloroplast-produced Nef
Plastid (chloroplast) transformation has emerged as
an attractive tool for plant biotechnologists (Maliga
2004; Bock 2007; Koop et al. 2007). The major
advantages of this technology are high-level foreign
protein accumulation, ranging between two and more
than 70% of TSP (Oey et al. 2008), and the absence
of epigenetic effects (gene silencing and position
effects). Moreover, the maternal plastid inheritance,
which prevents pollen-mediated gene ﬂow from the
genetically modiﬁed plant to other plants, greatly
increases transgene containment (Bock 2001; Ruf
et al. 2007; Svab and Maliga 2007). Transgenic
chloroplasts as bioreactors for the production of
vaccines and biopharmaceuticals are very promising
as indicated from a number of published studies
(Daniell 2006).
Zhou and colleagues have explored the potential of
the plastid transformation as an alternative tool to
produce high levels of HIV-1 Nef and p24 antigens in
plant cells (Zhou et al. 2008). For this purpose, a
series of constructs were designed to express the p27
Nef protein either alone or as p24-Nef or Nef-p24
fusion proteins. As the analysis of the codon usage in
the native p24 and nef gene revealed signiﬁcant
differences from that in the (AT)-rich plastid genome,
both genes were re-synthesized. All constructs were
utilised to transform tobacco (cv. Petite Havana)
plastids and the transplastomic (i.e., plastid-trans-
formed) lines were puriﬁed to homoplasmy, the
genetically stable state in which all wild-type plastid
genomes are eliminated and a homogeneous popula-
tion of transgenic plastid genomes is present (Bock
2001; Maliga 2004). Analysis of p24-Nef and Nef-
p24 fusion proteins showed that both can be
expressed to relatively high levels in chloroplasts.
Some lines harbouring nef as single gene, displayed a
mutant phenotype with green and yellow sectors. nef
mRNA and protein expression analysis showed that
high levels of nef transcripts accumulated only in the
yellow tissue while low amounts of nef mRNA were
found in the green sectors. Consistent with this, when
expression was analyzed at the protein level, high
accumulation levels of Nef were seen only in the
yellow plants (Zhou et al. 2008). Sequencing of the
promoter region in several independent green and
yellow lines showed that the phenotype was due to an
homologous recombination event between a short and
a full-length version of the tobacco plastid ribosomal
RNA operon promoter. These results indicate that, if
expressed to high levels, the Nef protein may be
deleterious to the chloroplast by interfering with
organellar functions (Zhou et al. 2008).
As the best results in terms of protein expression
levels were obtained with the p24-Nef fusion pro-
tein, the correspondent gene was cloned in a new
expression vector constructed to avoid recombina-
tion events. This construct was introduced into the
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123tobacco and tomato plastid genomes. Transplastomic
tobacco and tomato plants were analysed and protein
accumulation was found to be close to 40% of the
leaf’s total protein and easily detectable by Coomas-
sie staining. Transcript and protein accumulation
were analysed in different ripening stage of tomato
fruit and while green tomatoes accumulated the
fusion protein to 2.5% of the total protein, the protein
was not detectable in ripe fruits. However, the use of
a green-fruited tomato variety, commercially avail-
able, seems the solution for the production of the
antigens in an edible fruit (Zhou et al. 2008). It is also
noteworthy that, despite the enormous expression
levels obtained with the optimized p24-nef fusion
gene, the transplastomic plants did not display the
same strong phenotype as the nef plants, suggesting
that fusion to p24 may alleviate the negative effects
of Nef on chloroplast function.
As the tobacco cultivar generally used for plastid
transformation is a relatively small variety (cv. ‘‘Petit
Havana’’), which produces only about 100–200 g of
leaf material per plant, the yield of recombinant
protein could be greatly increased if a high biomass
cultivar was used. Philip Dix’s group in Maynooth
reports the production of high yields of HIV p27 Nef
protein through plastid transformation of tobacco cv.
Maryland Mammoth, a high biomass cultivar which
produces about 1.5 kg leaf material per plant (M. S.
McCabe et al., unpublished data).
All the transplastomic plants expressing Nef exhib-
ited a yellow phenotype, as had previously been found
in plants expressing the HIV p24 protein using an
otherwise identical vector (McCabe et al. 2008). The
cause of the pigment deﬁciency has not been explored
furtherintheseplants.Itresultsinareductioningrowth
rate but the plants still grow well, remain vigorous and
reach ﬂowering after about 120 days. Seedling tests
revealed 100% yellow seedlings with no sign of
segregation, supporting homoplasmy of these lines,
which was conﬁrmed by long-range PCR. Nef expres-
sion levels were estimated to be 300 lg/g fresh weight
(equally *6% of TSP). The puriﬁcation of Nef from
Maryland Mammoth chloroplasts by ammonium sul-
phate precipitation followed by citric acid/sodium
citrate treatment and cation exchange chromatogra-
phy, a procedure previously used with success with
HIV p24 (McCabe et al. 2008), was unsuccessful and
the protein appeared unstable under these extraction
conditions. Reﬁnements in the extraction procedure
are under investigation (M. S. McCabe et al., unpub-
lisheddata).ThetobaccocultivarMarylandMammoth
is a strong candidate for the production of commercial
quantities of recombinant HIV proteins (including
Nef), via chloroplast transformation.
Conclusions
The last AIDS epidemic update indicates that a
vaccine able to induce neutralizing immunity is
a priority. The goal of the HIV-1 vaccination should
be to obtain an antibody barrier able to neutralize the
virus preventing viral entry and to induce a durable
cellular immune response overcoming strain-speciﬁc
immunity (Walker and Burton 2008). In this context
the design of a multi-antigen protein vaccine should
include different viral components conserved among
several strains. Studies concerning the generation of
multi-component HIV vaccines, containing Nef, have
been published (Goepfert et al. 2007; Voss et al.
2003; Maggiorella et al. 2007) and the results are
very promising.
As the vast majority of people who need HIV
vaccine live in developing countries, low-cost pro-
duction should be considered an important issue
together with the effectiveness of the vaccine design.
In this context plants represent a cost-effective
alternative to the expression systems frequently used
to produce vaccine components (Ma et al. 2005;
Schillberg et al. 2005).
In the present review we gave an overview of the
different expression strategies developed to over
produce HIV neutralizing antibodies and HIV anti-
gens in plants, speciﬁcally focusing the attention on
Nef protein.
Results obtained with the expression of HIV
neutralising antibodies in transgenic plants are very
promising, and indicate that plant-produced antibod-
ies are generally comparable in terms of antigen
binding and HIV neutralization activity to their CHO-
derived counterparts. Moreover, the high expression
yields documented for the 2G12 antibody produced in
maize seed endosperm make this plant expression
platform particularly attractive and economically
advantageous (Ramessar et al. 2008). Yet, a possible
limitation to the applicability in therapy of plant-
derived mAbs could be represented by the difference
in N-glycan composition from their mammalian
Transgenic Res (2009) 18:499–512 507
123counterpart which could lead to immunogenicity
problems (Jin et al. 2008). To address this limitation
different strategies have been successfully adopted to
modify the glycosylation pattern of plant derived
mAbs which include the modulation of plant glyco-
sylation using RNA interference (Cox et al. 2006;
Strasser et al. 2008), the co-expression of speciﬁc
human glycosyltransferases (Bakker et al. 2006;
Fujiyama et al. 2007), or the exploitation of speciﬁc
knockout transgenic lines that synthesize complex
N-glycans lacking immunogenic xylose and fucose
epitopes (Scha ¨hs et al. 2007) and/or the retention of
the immunoglobulin in the endoplasmic reticulum
(ER) (Triguero et al. 2005).
Inthisworkweparticularlyfocusedourattentionon
thedifferentstrategiesattemptedtoexpressHIV-1Nef
in planta. The highest Nef accumulation has been
obtained in chloroplasts of transplastomic vegetative
tissueasfusiontop24yieldingupto40%ofTSP(Zhou
et al. 2008), while expression of Nef alone in this
organelle resulted in a much lower accumulation
suggesting that protein degradation can be a limiting
factoralsoinplastids.AttemptstoexpressNefalonein
thecytosoldemonstratedverylowaccumulationlevels
below 0.5% of TSP (Marusic et al. 2007), although it
hasbeenfoundthatanchoringNeftothecytosolicface
of the ER by addition of a C-terminal tail-anchor
domain can improve protein stability and accumula-
tion (Barbante et al. 2008). The strategy of targeting
Nef alone into the lumen of the ER proved deleterious
for its stability, probably because of folding defects
recognized by the quality control machinery. In this
case Nef fusion to the vacuolar storage protein zeolin
increases accumulation levels by preventing protein
degradation inthe secretory pathway (de Virgilio et al.
2008).Theresultsare promising,however,they donot
equal those obtained in leaf chloroplasts.
In conclusion, although absolute comparisons in
terms of protein yield between the different expres-
sion strategies discussed cannot be made, general
considerations can be drawn from the results obtained
in this collaborative research. The expression of Nef
protein alone in different cell compartments tended to
result in low accumulation levels. Conversely, the
fusion to stabilizing protein components appears to be
at the moment the most promising approach to
enhancing yields, although in this case efﬁcient
extraction and puriﬁcation of the antigen still has to
be demonstrated.
In the light of these results, as the immunogenicity
of a number of HIV-1 antigens produced in plants has
been already reported, future work will move on from
optimisation of expression and aim at testing the
immunological properties of plant expressed Nef to
verify the possibility of including it with other HIV
antigens, already expressed in plants, in a potential
HIV vaccine.
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